Pfizer’s Buying Spree Continues With GBT, Gaining A Sickle Cell Disease Franchise

 
• By Jessica Merrill

Pfizer has reached a deal to buy Global Blood Therapeutics for $5.4bn, gaining the sickle cell therapy Oxbryta and building on efforts to reach underserved patient groups.

Sickle Cell Disease
Pfizer is expanding in the sickle cell disease space with GBT acquisition • Source: Shutterstock

More from Blood and Clotting

More from Therapy Areas